Intercept Pharmaceuticals (ICPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2022 | 12-2021 | 12-2020 | 12-2019 | 12-2018 | |
| Sales | 285,710 | 260,750 | 233,970 | 252,002 | 179,804 |
| Cost of Goods | 984 | 1,205 | 2,353 | 4,212 | 2,519 |
| Gross Profit | 284,726 | 259,545 | 231,617 | 247,790 | 177,285 |
| Operating Expenses | 353,926 | 360,156 | 461,697 | 560,429 | 463,294 |
| Operating Income | -68,216 | -100,406 | -229,727 | -312,427 | -285,490 |
| Interest Expense | 21,385 | 54,419 | 48,054 | 41,144 | 30,523 |
| Other Income | -85,257 | 18,473 | 4,381 | 8,890 | 6,771 |
| Pre-tax Income | -174,858 | -136,352 | -273,400 | -344,681 | -309,242 |
| Net Income Continuous | -174,858 | -136,352 | -273,400 | -344,681 | -309,242 |
| Net Income Discontinuous | 396,674 | 44,926 | -1,480 | N/A | N/A |
| Net Income | $221,816 | $-91,426 | $-274,880 | $-344,681 | $-309,242 |
| EPS Basic Total Ops | 6.56 | -2.87 | -8.34 | -10.89 | -10.86 |
| EPS Basic Continuous Ops | -5.17 | -4.28 | -8.29 | -10.89 | -10.86 |
| EPS Basic Discontinuous Ops | 11.72 | 1.41 | -0.04 | N/A | N/A |
| EPS Diluted Total Ops | 6.56 | -2.87 | -8.34 | -10.89 | -10.86 |
| EPS Diluted Continuous Ops | -5.17 | -4.28 | -8.29 | -10.89 | -10.86 |
| EPS Diluted Discontinuous Ops | 11.72 | 1.41 | -0.04 | N/A | N/A |
| EPS Diluted Before Non-Recurring Items | -2.46 | -3.39 | -8.34 | -10.89 | -10.86 |
| EBITDA(a) | $-65,648 | $-59,587 | $-194,274 | $-285,747 | $-265,368 |